The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Immunoglobulin supplementation reduces infections in patients with myeloma receiving immunotherapy
Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, discusses the benefit of immunoglobulin supplementation in lowering infection rates among patients with multiple myeloma receiving novel immunotherapies. He emphasizes its importance in heavily pretreated and high-risk patients. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So we evaluated more than 150 patients who received immunoglobulin supplementation while they were receiving treatment for myeloma. It seems that the supplementation with immunoglobulin resulted in a significant reduction in the rate of infections. This was mostly pronounced and more significant in patients who received bispecific antibodies targeting BCMA and was also seen mostly in patients treated after the third or fourth line of therapy...
So we evaluated more than 150 patients who received immunoglobulin supplementation while they were receiving treatment for myeloma. It seems that the supplementation with immunoglobulin resulted in a significant reduction in the rate of infections. This was mostly pronounced and more significant in patients who received bispecific antibodies targeting BCMA and was also seen mostly in patients treated after the third or fourth line of therapy. So the impact in patients at earlier stages of the disease was not so high as it was in patients who were at later stages of the disease. So importantly, we did see a significant reduction in the number of infections, even for patients who previously had infections before they started immunoglobulin supplementation. So we believe that for selected patients and especially those who receive BCMA-targeted by specific antibodies and those who have very low levels of immunoglobulin, the supplementation with Ig should be incorporated in the everyday clinical practice.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
